Assessing the impact of cardiovascular events on health-related quality of life outcomes in DAPA-HF
Event: ESC Congress 2021 - The Digital Experience
Topic: Pharmacotherapy
Session: Chronic heart failure e-posters
Evaluating the key predictors of health-related quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial
Event: ESC Congress 2021 - The Digital Experience
Topic: Pharmacotherapy
Session: Chronic heart failure e-posters
AFFIRM-AHF Cost-Effectiveness Modelling Results in 4 Countries (US, UK, CH & IT).
Event: Heart Failure 2021
Topic: Chronic Heart Failure
Session: Clinical, Quality of Life and Cost-Effectiveness learnings from the AFFIRM-AHF Clinical Trial
AFFIRM-AHF-based multinational cost-effectiveness analysis of intravenous ferric carboxymaltose for the treatment of iron deficiency in an acute heart failure setting
Event: Heart Failure 2021
Topic: Pharmacotherapy
Session: Late-Breaking Trials 2
Budget impact evaluation of the DAPA-HF trial: is dapagliflozin cost-saving for the treatment of heart failure with reduced ejection fraction?
Event: Heart Failure 2021
Topic: Cardiovascular Epidemiology
Session: ePoster session
The relationship between duration of heart failure, serum potassium concentration and adverse clinical outcomes
Event: ESC Congress 2020
Topic: Epidemiology, Prognosis, Outcome
Session: The Different and Changing Faces of Heart Failure
Estimating the burden of hyperkalaemia in the UK in high-risk patient populations
Event: ESC Congress 2020
Topic: Epidemiology
Session: Risk Factors and Prevention ePosters
Assessing the relationship between serum potassium variability and the risk of hyperkalaemia and adverse clinical outcomes
Event: ESC Congress 2020
Topic: Epidemiology
Session: Risk Factors and Prevention ePosters
ESC 365 is supported by
